Method for producing ferulyl stanol derivatives
    6.
    发明授权
    Method for producing ferulyl stanol derivatives 失效
    铁醇甾烷醇衍生物的制备方法

    公开(公告)号:US4897224A

    公开(公告)日:1990-01-30

    申请号:US831853

    申请日:1986-02-24

    IPC分类号: A61K31/575 C07J9/00

    CPC分类号: A61K31/575 C07J9/00

    摘要: A fertility drug is made from an effective component comprising ferulyl stanol derivative represented by the following formula (I) and/or phytosterol fatty acid ester represented by the following formula (II). Such an effective component may be extracted from Job's tears seed, preferably bran thereof. A synthetic method of producing ferulyl phytostanol derivative is also disclosed. ##STR1##

    摘要翻译: 生育药由含有由下式(I)表示的阿魏尔甾烷醇衍生物和/或下式(II)表示的植物甾醇脂肪酸酯的有效成分构成。 这种有效成分可以从Job的眼泪种子中提取出来,最好是麸皮。 还公开了一种生产阿魏酰植物甾醇衍生物的合成方法。 式(I)(R:CH 3或C 2 H 5)

    Method of manufacturing a packaged soybean curd
    7.
    发明授权
    Method of manufacturing a packaged soybean curd 失效
    包装大豆凝乳的制造方法

    公开(公告)号:US4303678A

    公开(公告)日:1981-12-01

    申请号:US174439

    申请日:1980-08-01

    CPC分类号: A23C20/025 A23L11/09

    摘要: A method of manufacturing a packaged soybean curd with a long shelf life without the inclusion of any artificial additives such as coagulating agents, germicides and the like; wherein soybean juice is subjected to lactic acid fermentation until its pH is reached to a value equal to or less than a value which is determined from the percentage of the solids content (5-16 wt. %) of soybean juice and then is subjected to heating (60.degree.-95.degree. C., 10-100 minutes) to adjust the curd tension to above 20 g.

    摘要翻译: 一种制造长寿命的包装大豆凝乳的方法,而不包括任何人造添加剂如凝结剂,杀菌剂等; 其中大豆汁进行乳酸发酵,直到其pH达到等于或小于由大豆汁的固体含量(5-16重量%)的百分比确定的值,然后进行 加热(60°-95℃,10-100分钟),将凝乳张力调节至20g以上。

    Antitumor agent and process for manufacturing said agent
    8.
    发明授权
    Antitumor agent and process for manufacturing said agent 失效
    抗肿瘤剂及其制造方法

    公开(公告)号:US4645667A

    公开(公告)日:1987-02-24

    申请号:US566074

    申请日:1983-12-27

    CPC分类号: C12P1/04

    摘要: This invention relates to an antitumor agent comprising as a main ingredient a chemically purified cell walls of microorganisms belonging to genus Bificobacterium having physical integrity of cell wall structure thereof, obtained without being subjected to chemical and/or physical destruction of said cell wall during removal of intracellular substances of said cell, and a process for manufacturing the same, which comprises the steps of; (a) treating said cells with surfactants, (b) treating said cells with proteases, nucleases, organic solvents and dilute acid, to remove intracellular substances out of said cells without destruction thereof, and (c) separating a chemically purified cell walls having physical integrity of cell wall structure thereof.

    摘要翻译: 本发明涉及一种抗肿瘤剂,其包含作为主要成分的化学纯化的细胞壁,所述微生物属于具有细胞壁结构的物理完整性的微生物,其细胞壁结构具有物理完整性,而不会在除去所述细胞壁时被化学和/或物理破坏所述细胞壁 所述细胞的细胞内物质及其制造方法,包括以下步骤: (a)用表面活性剂处理所述细胞,(b)用蛋白酶,核酸酶,有机溶剂和稀酸处理所述细胞,以除去所述细胞中的细胞内物质而不破坏细胞,和(c)分离具有物理 细胞壁结构的完整性。

    Process for preparing a therapeutic agent
    9.
    发明授权
    Process for preparing a therapeutic agent 失效
    制备治疗剂的方法

    公开(公告)号:US4054648A

    公开(公告)日:1977-10-18

    申请号:US496814

    申请日:1974-08-12

    IPC分类号: A61K35/50 A61K38/00 A61P35/02

    CPC分类号: A61K35/50

    摘要: Therapeutic agents are prepared by:A. grinding placenta with water or diluted physiological saline to form an emulsion, and acidifying the emulsion with a mixture of aqueous acetic acid and hydrochloric acid, to 0.5 to 2.0N;B. heating the acidified emulsion;C. cooling the emulsion, removing insoluble protein by centrifugation, neutralizing the emulsion with an alkali solution, centrifuging said emulsion to remove insoluble matter and collecting a clear supernatant;D. concentrating the supernatant, and dialyzing the resulting concentrated liquid through a dialysis membrane, or filtrating said supernatant through a membrane filter to obtain a dialyzed fluid or filtrate;E. subjecting the dialyzed fluid or filtrate, after concentration to column chromatography, to obtain any one of fractions, of 0.96 - 1.82 in distribution coefficient with Sephadex G-25, of 0.35 - 1.24 with Sephadex G-15, or of 0.35 - 1.25 with Sephadex G-10; andF. lyophilizing the fraction.

    摘要翻译: 治疗剂通过以下方法制备:

    Fine carrier particles sensitized with acylated antibody for antigen
detection
    10.
    发明授权
    Fine carrier particles sensitized with acylated antibody for antigen detection 失效
    用酰化抗体敏化用于抗原检测的细载体颗粒

    公开(公告)号:US4591571A

    公开(公告)日:1986-05-27

    申请号:US601522

    申请日:1984-04-18

    摘要: Reagents for detecting antigen contained in body fluid or urine according to the immunological agglutination or agglutination inhibition reaction and comprising an antibody adsorbed on fine carrier particle to be sensitized as an effective constituent, and is characterized by acylating said antibody.Owing to such acylation, the reagent can correctly detect antigen without any influence of substance contained in sample which has inevitably caused nonspecific agglutination reaction according to the prior art.

    摘要翻译: 根据免疫凝集或凝集抑制反应检测体液或尿中含有的抗原的试剂,其含有被吸附在敏化剂作为有效成分的细载体颗粒上的抗体,其特征在于酰化所述抗体。 由于这样的酰化,试剂可以正确检测抗原,而不受样品中所含物质的任何影响,根据现有技术不可避免地引起非特异性凝集反应。